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Abstract
Objective: CareHPV is a human papillomavirus (HPV) DNA test for low-resource settings (LRS). This study
assesses optimum triage strategies for careHPV-positive women in LRS.
Methods: A total of 2,530 Chinese women were concurrently screened for cervical cancer with visual inspection
with acetic acid (VIA), liquid-based cytology and HPV testing by physician- and self-collected careHPV, and
physician-collected Hybrid Capture 2 (HC2). Screen-positive women were referred to colposcopy with biopsy and
endocervical curettage as necessary. HPV-positivity was defined as ≥1.0 relative light units/cutoff (RLU/CO) for
both careHPV and HC2.  Primary physician-HC2, physician-careHPV and self-careHPV and in sequential
screening with cytology, VIA, or increased HPV test-positivity performance, stratified by age, were assessed for
cervical intraepithelial neoplasia (CIN) grade 2/3 or worse (CIN2/3+) detection.
Results: The sensitivities and specificities of primary HPV testing for CIN2+ were: 83.8%, 88.1% for physician-
careHPV; 72.1%, 88.2% for self-careHPV; and 97.1%, 86.0% for HC2. Physician-careHPV test-positive women
with VIA triage had a sensitivity of 30.9% for CIN2+ versus 80.9% with cytology triage. Self-careHPV test-
positive women with VIA triage was 26.5% versus 66.2% with cytology triage. The sensitivity of HC2 test-positive
women with VIA triage was 38.2% versus 92.6% with cytology triage. The sensitivity of physician-careHPV testing
for CIN2+ decreased from 83.8% at ≥1.0 RLU/CO to 72.1% at ≥10.00 RLU/CO, while the sensitivity of self-
careHPV testing decreased from 72.1% at ≥1.0 RLU/CO to 32.4% at ≥10.00 RLU/CO; similar trends were seen
with age-stratification.
Conclusions: VIA and cytology triage improved specificity for CIN2/3 than no triage. Sensitivity with VIA
triage was unsuitable for a mass-screening program. VIA provider training might improve this strategy. Cytology
triage could be feasible where a high-quality cytology program exists. Triage of HPV test-positive women by
increased test positivity cutoff adds another LRS triage option.
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Introduction
Cervical cancer incidence and mortality have declined in
countries  where  cytology-based  screening  has  been
implemented (1). Cervical cancer remains the fourth most
common female cancer in the world (2), however, because
of  the  disease-burden  disparity  between  high  and  low-
income countries,  which do not  have  effective  national
cervical  cancer  screening  programs  (3).  Because  of  the
complexity,  need  for  trained  personnel,  and  frequent
follow-up (4,5), it is difficult to establish cytology-based
cervical cancer screening programs in low-resource settings
(LRS), where there are no sufficient health infrastructure,
personnel and equipment.
Alternative screening methods have emerged as options
for LRS, including visual inspection with acetic acid (VIA)
and  human  papillomavirus  (HPV)  DNA  tests.  The
sensitivity of VIA is variable, ranging from 31% to 95% for
detection of cervical intraepithelial neoplasia (CIN) grade 2
or worse (CIN2+) (6). Another option is DNA testing for
carcinogenic HPV. HPV testing has been shown to reduce
CIN2+  prevalence  more  than  VIA  (7)  and  to  be  more
effective than VIA or cytology in reducing cervical cancer
mortality with a single round of screening (8). The United
States  Food  and  Drug  Administration’s  first-approved
HPV  DNA  test,  Hybrid  Capture  2  (HC2;  Qiagen,
Gaithersburg, MD, USA) has been widely used in studies
of  primary  HPV  testing.  HC2  has  been  approved  for
diagnostic  use  at  a  positivity  cutoff  of  1.0  relative  light
units/cutoff  (RLU/CO)  or  higher.  CareHPV  (Qiagen,
Gaithersburg, MD) is a more affordable, simplified HPV
DNA  test  developed  for  use  in  low-income  countries.
CareHPV has been approved for diagnostic use at a cutoff
of  1.0  RLU/CO  or  higher  by  China  Food  and  Drug
Administration  (CFDA).  The  careHPV  test  has  been
shown  to  have  comparable  performance  to  HC2  in
screening for CIN2+ using cervical samples, takes 2.5 h to
run, and can be conducted by technicians in varied working
conditions (9).
HPV DNA testing offers the opportunity of using self-
collected  vaginal  samples  for  primary  cervical  cancer
screening. Self-collection can be done by a woman herself
without a pelvic exam, health professionals, or a visit to a
health clinic, and thus presents a viable option for primary
screening in LRS. A pooled analysis of 13,000 women from
China showed that, with HC2 DNA testing, self-HPV was
as sensitive as liquid-based cytology (LBC) and superior to
VIA in detection for high-grade CIN and that physician-
HPV testing was more sensitive but similarly specific than
self-HPV testing (10). A multi-country analysis found that
self-careHPV and physician-careHPV testing had higher
sensitivities than cytology or VIA (11).
Primary HPV testing is characteristic of a high average
sensitivity,  albeit  a  low  average  specificity  for  CIN2+
detection in comparison to VIA or cytology (12), and as
such,  HPV-positive  women  with  transient  or  non-
progressing high-risk (hr) HPV infections are at risk for
unnecessary detection or overtreatment. Therefore, triage
of  hrHPV-positive  women  is  appropriate  for  clinical
management  (13).  However,  few  studies  discussed  the
performance of careHPV test by triage methods and across
test positivity cutoffs stratifed by age. This study evaluates
the clinical performances of primary self-careHPV triage
and primary physician-careHPV triage by VIA, cytology,
and test positivity cutoff with age stratification for high-
grade CIN detection, compared with primary physician-
HC2 triage,  VIA and cytology,  in order to explore new
approaches to current screening algorithms in LRS. Both
HPV tests are approved for use at a cutoff of 1.0 RLU/CO
or higher, and so we sought to explore the utility in triage
by increasing test positivity cutoff for research investigation
only, without changing the primary screening cutoffs. This
study contributes data to the future discussions around the
possible  off-label  use  of  raising  HPV  DNA  testing
positivity to increase test specificity in areas where other
triage methods are not viable.
Materials and methods
Study population and ethics approval
Women aged 30 to 54 years  were recruited to undergo
cervical  cancer  screening  from May  10th  to  June  15th,
Chinese Journal of Cancer Research, Vol 29, No 6 December 2017 497
© Chinese Journal of Cancer Research. All rights reserved. www.cjcrcn.org Chin J Cancer Res 2017;29(6):496-509
2007  from  two  communes  in  each  of  Wuxiang  and
Xiangyuan counties,  Shanxi  Province,  China.  The four
communes  were  selected  through a  simple  randomized
sampling method from the list of all communes in these
two  counties.  Then  all  eligible  women  in  these  four
communes were invited to attend the screening. Women
were study-eligible if they had no history of CIN, pelvic
radiation, hysterectomy, were not currently pregnant and
were able  to  provide informed consent.  This  study was
approved  by  the  Institutional  Review  Board  of  Cancer
Institute/Hospital, Chinese Academy of Medical Sciences
(CICAMS) and the Human Subjects Protection Committee
of  Program  for  Appropriate  Technology  in  Health
(PATH).
Screening procedures
Cervical cancer screenings were carried out at Women and
Children’s Hospitals in Wuxiang and Xiangyuan. A trained
health care worker provided each woman with informed
consent and administered a questionnaire regarding socio-
demographic, reproductive, and behavioral information in a
confidential interview.
Under the instruction of a nurse in clinic, each woman
provided a vaginal-brush specimen for the self-careHPV
test, and two vaginal nylon-swab specimens for storage. A
physician then performed a speculum exam and collected
cervical specimens. One cervical specimen was collected for
the physician-careHPV test,  one cervical  specimen was
collected for liquid-based cytology classification (SurePath,
Becton Dickinson, Franklin Lakes,  NJ, USA; LBC) and
HC2 testing, and two cervical specimens using nylon swabs
were collected for storage. All women had VIA followed by
a digital colposcopy (Goldway, Shenzhen, China).
As  described  in  previous  studies  from  our  lab  (9),  if
women  had  an  abnormal  colposcopy  exam,  directed
cervical biopsies were taken where lesions were visiable.
Endocervical  curettage (ECC) was performed if  women
had  an  unsatisfactory  colposcopy  exam  (the  squamo-
columnar junction was not completely visable), if the lesion
extended into the endocervical canal and if the lesions were
inaccessible to biopsy.  Cytological  slides were classified
according to the Bethesda system. Women with negative
colposcopy results  but  positive  LBC results,  defined as
atypical  squamous  cells-cannot  exclude  high-grade
squamous  intraepithelial  lesions  or  worse  (ASC-H+);
unsatisfactory cytology reading; a positive HC2 test; or a
positive  careHPV  test,  were  called  back  to  undergo  a
second colposcopy exam, where four-quadrant biopsies of
the  cervical  squamocolumnar  junction  and  ECC  were
taken.  Women found to  have  CIN2+ were  offered free
treatment according to local clinical guidelines. The study
methods have been previously published (9).
Screening tests
VIA
VIA positivity was defined as observing a distinct, dense,
non-moveable acetowhite areas in the transformation zone
near the squamocolumnar junction of the cervix, visible 1
min  after  application  of  3%  to  5%  acetic  acid.  Visual
inspection was performed by nurse midwives.
HPV testing
HPV  infection  was  assessed  using  the  HC2  assay
(QIAGEN, Gaithersburg,  Maryland) and careHPV test
(QIAGEN,  Gaithersburg,  Maryland).  HC2  assay  was
conducted  using  the  residual  LBC  medium  after
processing. The HC2 assay detects a pool of 13 high-risk
HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68). The careHPV assay is broadly based on the
HC2 assay with some important modifications for LRS,
including faster assay time, adaptability to a wide range of
conditions, and the targeting of 14 high-risk HPV types
(HPV66 in addition to the 13 high-risk HPV genotypes
detected  by  HC2  assay).  Both  HC2  and  careHPV
positivities were calculated at 1.0 RLU/CO (approximately
equal  to  1.0  pg  DNA  per  mL)  according  to  the
manufacturer’s recommendation. Trained local technicians
performed careHPV testing at the field sites in Shanxi. The
HC2  assay  was  performed  by  technicians  at  CICAMS,
Beijing.
Cytology and histology
Preparation and reading of  cytological  and histological
slides were done at CICAMS by a cyto-pathologist and a
pathologist.  The  Bethesda  and  the  CIN  classification
systems were used for cytology and histology, respectively.
All abnormal slides and 10% of normal histological and
cytological slides were randomly selected to be read by an
external  pathologist  in Canada,  who was blinded to the
CICAMS  diagnoses.  If  the  diagnoses  were  not  in
agreement, the final diagnosis was based on the Canadian
pathologist’s  reading  with  discussion  of  any  discordant
readings with the Chinese pathologist. The final diagnosis
for each woman was based on the highest reading across all
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histological findings, including directed and four-quadrant
biopsies and ECC. If a biopsy had not been indicated or if
the histology finding was negative for a woman, then she
was assessed as negative for CIN.
Statistical analysis
Analyses were focused on the clinical performances of self-
careHPV and physician-careHPV as  primary screening
methods.  HPV DNA test-positive  women were  triaged
with either VIA or cytology if CIN2+ and CIN grade 3 or
worse (CIN3+) were detected, in comparison to VIA and
cytology as primary screening, or HC2 followed by VIA or
cytology triage. Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), Youden’s
index  and  area  under  the  curve  (AUC)  of  the  receiver
operating  characteristics  (ROC)  of  each  strategy  were
calculated,  as  well  as  the  number  of  CIN2+  or  CIN3+
women  detected  per  strategy  and  the  number  of
colposcopies  examined per CIN2+ or CIN3+ detection.
McNemar’s  test  was  used to evaluate  the differences  in
sensitivities and specificities between strategies. Chi-square
test was used to compare the differences in PPV and NPV.
The z-test was used to evaluate for differences in AUC.
The  clinical  performance  of  self-careHPV,  physician-
careHPV and physician-HC2 primary screening was also
calculated at different cutoffs of test positivity (1.0, 2.0, 5.0
and 10.0 RLU/CO).
The mean menopausal age of the study population was
46.7 years old, and so the study population was stratified
into two age groups, women aged 30 to 44 years and 45 to
54 years. The above analyses were performed among the
stratified age groups.
When  performing  the  pairwise  comparison  among
different strategies, a two-sided α error level of 0.05 was
adjusted to the value that equaled to 0.05 divided by the
number  of  comparison  on  basis  of  the  Bonferroni
correction. Otherwise, a P value less than or equal to 0.05
(two-sided) was considered statistically significant. Analyses
were done using IBM SPSS Statistics (Version 20.0; IBM
Corp., New York, USA).
Results
Study participants
Of the 3,721 eligible women invited to participate, 2,530
(68.0%) came for cervical cancer screening. One hundred
and  forty-two  women  did  not  return  for  callback
examinations. Besides these 142 women, 50 women with
unsatisfactory cytology and 1 woman with missing VIA
were also excluded from the analysis. Thus, a total of 2,337
women with complete results were included in the analysis
(Figure 1).
Among women included in the final population analysis,
the mean age was 43.4±6.2 years old, and there were 1,350
women (57.8%, 1,350/2,337) aged at 30–44 years and 987
(42.2%, 987/2,337) aged at 45–54 years, respectively. The
mean age of sexual debut was 20.5±2.4 years, and the mean
age  of  menopause  was  46.7±4.2  years.  Only  4  women
(0.2%,  4/2,337)  were  currently  using  hormonal
contraceptives,  and  81.3%  (1,900/2,337)  had  been
sterilized.  The mean number of  live-births was 2.7±1.0.
Nearly all of women were currently married and had never
smoked. The HPV positive rates were 14.0% (328/2,337)
of physician-careHPV, 13.6% (317/2,337) of self-careHPV
and 16.4% (384/2,337) of physician-HC2, respectively. Six
percent of women (140/2,337) had an abnormal VIA result
and  5.4%  (127/2,337)  were  cytology  grade  ASC-H+.
Finally, 2.4% (56/2,337) were diagnosed as CIN1, 1.9%
(45/2,337) as CIN2 and 1.0% (23/2,337) as CIN3+.
Primary screening performance of physician- and self-
collected careHPV compared to other screening methods
for CIN2+ and CIN3+ detection
When  comparing  the  sensitivity  of  primary  screening
methods,  physician-careHPV  testing  for  CIN2+  was
significantly higher than VIA (83.8% vs. 39.7%, P<0.0001),
but lower than that of HC2 testing (97.1%, P=0.004), and
comparable  to  cytology  (85.3%,  P=1.000)  (Table  1).  In
terms  of  the  specificity  of  primary  screening  methods,
physician-careHPV for CIN2+ was significantly lower than
cytology  and  VIA  (88.1%  vs.  97.0%  and  95.0%,  all
P<0.0001) and higher than HC2 (86.0%, P<0.0001). No
significant differences of sensitivity and specificity were
observed between primary physician- careHPV testing vs.
self-careHPV  testing  (sensitivity:  83.8%  vs.  72.1%,
P=0.057; specificity: 88.1% vs. 88.2%, P=0.890). Youden’s
index for CIN2+ ranged from 83.0% for HC2 testing to
34.7% for VIA, and was 71.9% for physician-careHPV and
60.2% for self-careHPV. However,  the AUCs were not
significantly  different  between physician-careHPV and
self-careHPV  (0.859  vs.  0.801,  P=0.075)  (Figure  2).  A
similar pattern was observed for CIN3+ detection (Table 2,
Figure 3).
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Comparision  of  primary  HPV  testing  with  VIA  and
cytology triage for CIN2+ and CIN3+ detection
The sensitivity of primary physician-careHPV for CIN2+
detection was 83.8%, which was comparable with cytology
triage (80.9%, P=0.500) and lower with VIA triage (30.9%,
P<0.0001) (Table 1). The specificity of primary physician-
careHPV  for  CIN2+  was  88.1%  and  increased  with
cytology triage (95.0%, P<0.0001) and VIA triage (99.2%,
P<0.0001).  The  number  of  colposcopies  per  CIN2+
decreased from 5.8 for primary screening using physician-
careHPV to 1.9 with VIA triage.  AUC was comparable
between  primary  physician-careHPV  screening  and
cytology triage (0.859 vs. 0.879, P=0.354), but decreased to
0.650 for VIA triage (P<0.001) (Figure 2). Youden’s index
showed the same trend.  PPV increased from 17.4% for
primary physician-careHPV screening to 52.5% with VIA
triage (all P<0.0001), while NPV was comparable. Similar
trends were observed for self-careHPV based strategies and
HC2 based strategies (Table 1, Figure 2).
The  sensitivity  of  physician-careHPV  with  cytology
triage for CIN2+ detection was 80.9%, higher than self-
careHPV with cytology triage of 66.2% (P=0.006) (Table 1).
For careHPV with VIA triage, there was no statistically
significant  difference  in  sensitivity  between  physician-
careHPV and self-careHPV (30.9% vs. 26.5%, P>0.05). Of
note, the sensitivity of HC2 with cytology triage was the
highest for CIN2+ detection (92.6%, P<0.001). Meanwhile,
there  were  no  statistically  significant  differences  of
specificity, PPV, NPV and the number of colposcopy per
CIN2+  between  primary  physician-careHPV  and  self-
careHPV with cytology triage and VIA triage (all P>0.05)
(Table 1).
The  clinical  performance  of  the  above  strategies  for
 
Figure 1 Study flowchart.
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CIN3+ detection followed similar trends (Table 2, Figure 3).
There were no statistically  significant  differences  for
CIN2+ or  CIN3+ detection for  HPV DNA testing and
cytology triage between 30 to 44 and 45 to 54 years old,
but among women aged 45 to 54 years, HPV DNA testing
with  VIA  triage  was  less  sensitive  for  CIN2+/CIN3+
detection  than  among  women  aged  30  to  44  years
(Supplementary Tables S1, S2).
Performance  of  HPV  testing  in  age-specific  primary
screening  at  different  positive  cutoffs  for  CIN2+  and
CIN3+ detection
For  CIN2+  detection  using  primary  careHPV  testing,
triaging  physician-careHPV  test-positive  women  by
increasing HPV test-positivity cutoff increased specificity
(from  88.1%  at  ≥1.0  RLU/CO  to  93.5%  at  ≥10.0
RLU/CO)  and  PPV (from 17.4% at  ≥1.0  RLU/CO to
25.0%  at  ≥10.0  RLU/CO),  but  decreased  referral  rate
Table 1 Primary and triage screening performance of physician- and self-collected careHPV at ≥1.0 RLU/CO for CIN2+ detection among
2,337 women, compared to VIA and cytology primary screening, and physician-HC2 triage strategies
Primary
Screening
Triage
strategy CIN2+ (N=68)
% (95% CI)
Colposcopy
per CIN2+ (N)Sensitivity Specificity PPV NPV Youden’sindex
Physician-
careHPV ≥
1.0 RLU/CO
None 57 83.8(73.3–90.7)
88.1
(86.7–89.3)
17.4
(13.7–21.9)
99.5
(99.0–99.7)
71.9
(70.1–73.7) 5.8
ASC-US+ 55 80.9(70.0–88.5)
95.0
(94.0–95.8)
32.5
(25.9–39.9)
99.4
(99.0–99.6)
75.9
(74.2–77.6) 3.1
VIA 21 30.9(21.2–42.6)
99.2
(98.7–99.5)
52.5
(37.5–67.1)
98.0
(97.3–98.5)
30.0
(28.1–31.9) 1.9
Self-
careHPV ≥
1.0 RLU/CO
None 49 72.1(60.4–81.3)
88.2
(86.8–89.5)
15.5
(11.9–19.8)
99.1
(98.5–99.4)
60.2
(58.2–62.2) 6.5
ASC-US+ 45 66.2(54.3–76.3)
96.4
(95.5–97.1)
35.4
(27.7–44.1)
99.0
(98.4–99.3)
62.6
(60.6–64.6) 2.8
VIA 18 26.5(17.5–38.0)
99.2
(98.7–99.5)
50.0
(34.5–65.5)
97.8
(97.1–98.3)
25.7
(23.9–27.5) 2.0
Physician-
HC2 ≥1.0
RLU/CO
None 66 97.1(89.9–99.2)
86.0
(84.5–87.4)
17.2
(13.7–21.3)
99.9
(99.6–100)
83.0
(81.5–84.5) 5.8
ASC-US+ 63 92.6(83.9–96.8)
94.4
(93.3–95.2)
33.0
(26.7–39.9)
99.8
(99.5–99.9)
87.0
(85.6–88.4) 3.0
VIA 26 38.2(27.6–50.1)
99.0
(98.5–99.0)
54.2
(40.3–67.4)
98.2
(97.5–98.6)
37.3
(35.3–39.3) 1.8
Cytology
(ASC-H+) None 58
85.3
(75.0–91.8)
97.0
(96.2–97.6)
45.7
(37.3–54.3)
99.5
(99.2–99.8)
82.3
(80.8–83.8) 2.2
VIA None 27 39.7(28.9–51.6)
95.0
(94.0–95.8)
19.3
(13.6–26.6)
98.1
(97.5–98.6)
34.7
(32.8–36.6) 5.2
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; VIA,
visual inspection with acetic acid; HC2, Hybrid Capture 2; ASC-H+, atypical squamous cells-cannot exclude high-grade squamous
intraepithelial lesions or worse; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value;
ASC-US+, atypical squamous cells of undetermined significance or worse.
 
Figure  2  Receiver  operating  characteristics  (ROC)  curves  of
physician-careHPV and self-careHPV using atypical squamous
cells of undetermined significance or worse (ASC-US+) or visual
inspection with acetic acid (VIA) triage at positivity cutoff ≥1.0
relative light units/cutoff (RLU/CO), for cervical intraepithelial
neoplasia (CIN) grade 2 or worse (CIN2+) detection among 2,337
women. AUC, area under the ROC curve.
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(from  14.0%  at  ≥1.0  RLU/CO  to  8.4%  at  ≥10.0
RLU/CO), sensitivity (from 83.8% at ≥1.0 RLU/CO to
72.1% at ≥10.0 RLU/CO) and the number of colposcopy
per  CIN2+ (from 5.8  at  ≥1.0  RLU/CO to  4.0  at  ≥10.0
RLU/CO) (Table 3). NPVs were ≥97% for all RLU/CO
cutoffs. For CIN2+ detection using self-careHPV testing, a
similar trend was observed, but in comparision to primary
care-HPV testing,  the sensitivity declined more rapidly
with increasing HPV test-positivity cutoffs (from 72.1%
at ≥1.0 RLU/CO to 32.4% at ≥10.0 RLU/CO) and more
colposcopies were needed per one CIN2+ detection (from
6.5  at  ≥1.0  RLU/CO  to  6.9  at  ≥10.0  RLU/CO).  For
CIN2+  detecting  using  physician-HC2  testing,  the
sensitivity  declined with increasing HPV test-positivity
cutoffs  but  remained  ≥82.0%  even  at  ≥10.0  RLU/CO.
Similar trends were observed for CIN3+ detection (Table 4),
and  there  was  no  statistical  significance  in  overall
sensitivities  between  women  aged  30  to  44  years,  and
women aged 44 to 54 years (Table 3, 4).
Table 2 Primary and triage screening performance of physician- and self-collected careHPV at ≥1.0 RLU/CO for CIN3+ detection among
2,337 women, compared to VIA and cytology primary screening, and physician-HC2 triage strategies
Primary
Screening
Triage
strategy CIN3+ (N=23)
% (95% CI)
Colposcopy
per CIN3+ (N)Sensitivity Specificity PPV NPV Youden’sindex
Physician-
careHPV ≥
1.0 RLU/CO
None 20 87.0(67.9–95.5)
86.7
(85.2–88.0)
6.1
(4.0–9.2)
99.9
(99.6–99.9)
73.6
(71.8–75.4) 16.4
ASC-US+ 19 82.6(62.9–93.0)
93.5
(92.4–94.5)
11.2
(7.3–16.9)
99.8
(99.5–99.9)
76.1
(74.4–77.8) 8.9
VIA 12 52.2(33.0–70.8)
98.8
(98.3–99.2)
30.0
(18.1–45.4)
99.5
(99.1–99.7)
51.0
(49.0–53.0) 3.3
Self-
careHPV ≥
1.0 RLU/CO
None 18 78.3(58.1–90.3)
87.1
(85.7–88.4)
5.7
(3.6–8.8)
99.8
(99.4–99.9)
65.3
(63.4–67.2) 17.6
ASC-US+ 16 69.6(49.1–84.4)
95.2
(94.3–96.0)
12.6
(7.9–19.5)
99.7
(99.3–99.8)
64.8
(62.9–66.7) 7.9
VIA 10 43.5(25.6–63.2)
98.9
(98.4–99.2)
27.8
(15.8–44.0)
99.4
(99.0–99.7)
42.4
(40.4–44.4) 3.6
Physician-
HC2 ≥1.0
RLU/CO
None 22 95.7(79.0–99.2)
84.4
(82.8–85.8)
5.7
(3.8–8.5)
99.9
(99.7–100)
80.0
(78.4–81.6) 17.5
ASC-US+ 21 91.3(73.2–97.6)
92.7
(91.5–93.6)
11.0
(7.3–16.2)
99.9
(99.7–100)
84.0
(82.5–85.5) 9.1
VIA 13 56.5(36.8–74.4)
98.5
(97.9–98.9)
27.1
(16.6–41.0)
99.6
(99.2–99.8)
55.0
(53.0–57.0) 3.7
Cytology
(ASC-H+) None 20
87.0
(67.9–95.5)
95.4
(94.4–96.2)
15.7
(10.4–23.1)
99.9
(99.6–100)
82.4
(80.9–83.9) 6.4
VIA None 13 56.5(36.8–74.4)
94.5
(93.5–95.4)
9.3
(5.5–15.2)
99.5
(99.2–99.8)
51.0
(49.0–53.0) 10.8
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; VIA,
visual inspection with acetic acid; HC2, Hybrid Capture 2; ASC-H+, atypical squamous cells- cannot exclude high-grade squamous
intraepithelial lesions or worse; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value;
ASC-US+, atypical squamous cells of undetermined significance or worse.
 
Figure  3  Receiver  operating  characteristics  (ROC)  curves  of
physician-careHPV and self-careHPV using atypical squamous
cells of undetermined significance or worse (ASC-US+) or visual
inspection with acetic acid (VIA) triage at positivity cutoff ≥1.0
relative light units/cutoff (RLU/CO), for cervical intraepithelial
neoplasia (CIN) grade 3 or worse (CIN3+) detection among 2,337
women. AUC, area under the ROC curve.
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Table 3 Performance of physician- and self-collected careHPV in age-specific primary screening, stratified by RLU/CO cutoffs, for CIN2+
detection among 2,337 women, compared to physician-HC2 testing
Age (year) Primaryscreening
Positivity cutoff
(RLU/CO)
% (95% CI)
Colposcopy per
CIN2+ (N)Referral
rate Sensitivity Specificity PPV NPV
30 to 54 Physician-
careHPV 1.00
14.0
(12.7–15.5)
83.8
(73.3–90.7)
88.1
(86.7–89.3)
17.4
(13.7–21.9)
99.5
(99.0–99.7) 5.8
2.00 11.8(10.5–13.1)
80.9
(70.0–88.5)
90.3
(89.0–91.5)
20.0
(15.7–25.1)
99.4
(98.9–99.6) 5.0
5.00 10.1(8.9–11.3)
76.5
(65.1–85.0)
91.9
(90.7–93.0)
22.1
(17.3–27.9)
99.2
(98.8–99.5) 4.5
10.00 8.4(7.3–9.6)
72.1
(60.4–81.3)
93.5
(92.4–94.5)
25.0
(19.5–31.5)
99.1
(98.6–99.4) 4.0
Self-careHPV 1.00 13.6(12.2–15.0)
72.1
(60.4–81.3)
88.2
(86.8–89.5)
15.5
(11.9–19.8)
99.1
(98.5–99.4) 6.5
2.00 10.9(9.7–12.2)
63.2
(51.4–73.7)
90.7
(89.4–91.8)
16.9
(12.8–22.0)
98.8
(98.2–99.2) 5.9
5.00 8.3(7.3–9.5)
47.1
(35.7–58.8)
92.8
(91.7–93.8)
16.4
(11.9–22.2)
98.3
(97.7–98.8) 6.1
10.00 6.5(5.5–7.5)
32.4
(22.4–44.2)
94.3
(93.3–95.2)
14.6
(9.8–21.1)
97.9
(97.2–98.4) 6.9
Physician-
HC2 1.00
16.4
(15.0–18.0)
97.1
(89.9–99.2)
86.0
(84.5–87.4)
17.2
(13.7–21.3)
99.9
(99.6–100) 5.8
2.00 14.3(12.9–15.8)
95.6
(87.8–98.5)
88.1
(86.8–89.4)
19.5
(15.6–24.0)
99.9
(99.6–100) 5.1
5.00 12.7(11.4–14.1)
91.2
(82.1–95.9)
89.6
(88.3–90.8)
20.9
(16.6–25.9)
99.7
(99.4–99.9) 4.8
10.00 11.5(10.3–12.9)
86.8
(76.7–92.9)
90.7
(89.5–91.9)
21.9
(17.4–27.3)
99.6
(99.2–99.8) 4.6
30 to 44 Physician-
careHPV 1.00
12.1
(10.4–13.9)
84.6
(70.3–92.8)
90.1
(88.3–91.6)
20.2
(14.8–27.1)
99.5
(98.9–99.8) 4.9
2.00 10.3(8.8–12.0)
84.6
(70.3–92.8)
91.9
(90.3–93.3)
23.7
(17.4–31.5)
99.5
(98.9–99.8) 4.2
5.00 8.7(7.3–10.3)
76.9
(61.7–87.4)
93.4
(91.9–94.6)
25.6
(18.6–34.2)
99.3
(98.6–99.6) 3.9
10.00 7.6(6.3–9.1)
74.4
(58.9–85.4)
94.4
(93.1–95.5)
28.4
(20.6–37.8)
99.2
(98.5–99.6) 3.5
Self-careHPV 1.00 12.7(11.0–14.6)
79.5
(64.5–89.2)
89.3
(87.5–90.9)
18.1
(13.1–24.6)
99.3
(98.7–99.7) 5.5
2.00 9.9(8.4–11.6)
64.1
(48.4–77.3)
91.8
(90.1–93.1)
18.8
(13.1–26.3)
98.8
(98.1–99.3) 5.3
5.00 8.1(6.8–9.7)
48.7
(33.9–63.8)
93.1
(91.6–94.3)
17.3
(11.3–25.4)
98.4
(97.5–99.0) 5.8
10.00 6.1(5.0–7.6)
28.2
(16.5–43.8)
94.5
(93.1– 95.6 )
13.3
(7.6–22.2 )
97.8
(96.8–98.5) 7.5
Physician-
HC2 1.00
14.6
(12.8–16.6)
97.4
(86.8–99.5)
87.9
(86.0–89.5)
19.3
(14.4–25.4)
99.9
(99.5–100) 5.2
2.00 12.7(11.1–14.6)
94.9
(83.1–98.6)
89.7
(87.9–91.2)
21.5
(16.0–28.2)
99.8
(99.4–100) 4.6
5.00 11.1(9.5–12.9)
92.3
(79.7–97.3)
91.3
(89.7–92.7)
24.0
(17.9–31.4)
99.8
(99.3–99.9) 4.2
10.00 10.0(8.5–11.7)
89.7
(76.4–95.9)
92.4
(90.8–93.7)
25.9
(19.3–33.9)
99.7
(99.2–99.9) 3.9
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Discussion
In over 2,300 screened women from a low-income rural
setting in China, we evaluated multiple triage strategies for
both self-careHPV and physician-careHPV testing in order
to expand the available options for secondary prevention of
cervical cancer through screening in LRS. In LRS where
screening is limited, the goal is to explore new screening
options  while  keeping  in  mind  that  there  is  no  single
strategy that is suitable across all environments. Instead, it
is up to each country to adapt a program that best suits the
needs of the country. Across the HPV-test positive triage
strategies we tested to detect CIN2/3, we found that both
VIA and cytology improve specificity than no triage at all.
However,  VIA  drops  lowered  sensitivity  to  a  level
unsuitable for a mass-screening program. We found that
triage  of  HPV-test  positive  women  by  increasing  test
positivity cutoff could improve specificity, but at a loss of
sensitivity.
Because HPV-positive women often have transient or
non-progressing hrHPV and are at risk for overtreatment if
only screened through HPV testing, sequential testing of
HPV-positive women with a second screening test could
raise the specificity of the screening strategy. The decision
to  triage  careHPV  positive  women  depends  on  the
resources required and possible harms (false positives and
unnecessary colposcopies) of the triage method, versus its
clinical  performance  in  detecting  cervical  cancer
precursors.  One  triage  strategy  of  HPV-test  positive
women would be to increase test  positivity cutoff.  This
would be the easiest secondary screening test to implement
in  LRS,  as  this  method  does  not  require  additional
screening  infrastructure,  simply  an  additional  test  on
already  collected  careHPV  samples  and  is  a  semi-
quantitative estimate of viral load, which has been shown to
predict  cervical  precancerous  lesions  (14,15).  Our  data
show that as the test cutoff increased, sensitivity decreased
and specificity  increased for  primary self-careHPV and
physician-careHPV testing. For CIN2+ detection among
women aged 30 to 54 years,  physician-careHPV testing
dropped  slightly  from  a  sensitivity  of  83.8%  at  1.0
RLU/CO  to  72.1%  at  10.00  RLU/CO,  while  the
Table 3 (continued )
Age (year) Primaryscreening
Positivity
cutoff
(RLU/CO)
% (95% CI) Colposcopy
per CIN2+ (N)Referral rate Sensitivity Specificity PPV NPV
45 to 54 Physician-
careHPV 1.00
16.7
(14.5–19.2)
82.8
(65.5–92.4)
85.3
(82.9–87.4)
14.5
(10.0–20.7)
99.4
(98.6–99.7) 6.9
2.00 13.8(11.8–16.1)
75.9
(57.9–87.8)
88.1
(85.9–90.0)
16.2
(10.9–23.3)
99.2
(98.3–99.6) 6.2
5.00 12.0(10.1–14.1)
75.9
(57.9–87.8)
90.0
(87.9–91.7)
18.6
(12.6–26.6)
99.2
(98.3–99.6) 5.4
10.00 9.5(7.8–11.5)
69.0
(50.8–82.7)
92.3
(90.4–93.8)
21.3
(14.2–30.6)
99.0
(98.1–99.5) 4.7
Self-careHPV 1.00 14.8(12.7–17.1)
62.1
(44.0–77.3)
86.6
(84.3–88.6)
12.3
(7.9–18.6)
98.7
(97.7–99.3) 8.1
2.00 12.3(10.4–14.5)
62.1
(44.0–77.3)
89.2
(87.1–91.1)
14.9
(9.6–22.3)
98.7
(97.7–99.3) 6.7
5.00 8.6(7.0–10.5)
44.8
(28.4–62.5)
92.5
(90.6–94.0)
15.3
(9.2–24.4)
98.2
(97.1–98.9) 6.5
10.00 6.9(5.5–8.6)
37.9
(22.7–56.0)
94.1
(92.4–95.4 )
16.2
(9.3–26.7 )
98.0
(96.2–98.8 ) 6.2
Physician-
HC2 1.00
18.9
(16.6–21.5)
96.6
(82.8–99.4)
83.4
(80.9–85.6)
15.0
(10.6–20.8)
99.9
(99.3–100) 6.7
2.00 16.4(14.2–18.9)
96.6
(82.8–99.4)
86.0
(83.7–88.1)
17.3
(12.2–23.8)
99.9
(99.3–100) 5.8
5.00 14.9(12.8–17.3)
89.7
(73.6–96.4)
87.4
(85.1–89.3)
17.7
(12.4–24.7)
99.6
(99.0–99.9) 5.7
10.00 13.6(11.6–15.9)
82.8
(65.5–92.4)
88.5
(86.3–90.4)
17.9
(12.3–25.3)
99.4
(98.6–99.7) 5.6
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HC2,
Hybrid Capture 2; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
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Table 4 Performance of physician- and self-collected careHPV in age-specific primary screening, stratified by RLU/CO cutoffs, for CIN3+
detection among 2,337 women, compared to physician-HC2 testing
Age (year) Primaryscreening
Positivity cutoff
(RLU/CO)
% (95% CI) Colposcopy per
CIN3+ (N)Referral rate Sensitivity Specificity PPV NPV
30 to 54 Physician-
careHPV 1.00
14.0
(12.7–15.5)
87.0
(67.9–95.5)
86.7
(85.2–88.0)
6.1
(4.0–9.2)
99.9
(99.6–99.9) 16.4
2.00 11.8(10.5–13.1)
87.0
(67.9–95.5)
89.0
(87.6–90.2)
7.3
(4.8–11.0)
99.9
(99.6–100) 13.8
5.00 10.1(8.9–11.3)
82.6
(62.9–93.0)
90.7
(89.4–91.8)
8.1
(5.2–12.3)
99.8
(99.5–100) 12.4
10.00 8.4(7.3–9.6)
78.3
(58.1–90.3)
92.3
(91.2–93.3)
9.2
(5.9–14.0)
99.8
(99.5–99.9) 10.9
Self-careHPV 1.00 13.6(12.2–15.0)
78.3
(58.1–90.3)
87.1
(85.7–88.4)
5.7
(3.6–8.8)
99.8
(99.4–99.9) 17.6
2.00 10.9(9.7–12.2)
69.6
(49.1–84.4)
89.7
(88.4–90.9)
6.3
(3.9–10.0)
99.7
(99.3–99.8) 15.9
5.00 8.3(7.3–9.5)
56.5
(36.8–74.4)
92.1
(91.0–93.2)
6.7
(4.2–11.8)
99.5
(99.1–99.7) 15.0
10.00 6.5(5.5–7.5)
39.1
(22.2–59.2)
93.9
(92.8–94.8)
6.0
(3.2–10.9)
99.4
(98.9–99.6) 16.8
Physician-
HC2 1.00
16.4
(15.0–18.0)
95.7
(79.0–99.2)
84.4
(82.8–85.8)
5.7
(3.8–8.5)
99.9
(99.7–100) 17.5
2.00 14.3(12.9–15.8)
95.7
(79.0–99.2)
86.5
(85.1–87.9)
6.6
(4.4–9.8)
100
(99.7–100) 15.2
5.00 12.7(11.4–14.1)
95.7
(79.0–99.2)
88.1
(86.7–89.4)
7.4
(4.9–11.0)
100
(99.7–100) 13.5
10.00 11.5(10.3–12.9)
91.3
(73.2–97.6)
89.3
(88.0–90.5)
7.8
(5.2–11.6)
99.9
(99.6–100) 12.8
30 to 44 Physician-
careHPV 1.00
12.1
(10.4–13.9)
91.67
(64.6–98.6)
88.6
(86.8–90.2)
6.8
(3.8–11.7)
99.9
(99.5–100) 14.8
2.00 10.3(8.8–12.0)
91.67
(64.6–98.5)
90.4
(88.7–91.9)
7.9
(4.5–13.6)
99.9
(99.5–100) 12.6
5.00 8.7(7.3–10.3)
83.33
(55.2–95.3)
92.0
(90.4–93.3)
8.6
(4.7–15.0)
99.8
(99.4–100) 11.7
10.00 7.6(6.3–9.1)
83.33
(55.2–95.3)
93.1
(91.6–94.4)
9.8
(5.4–17.1)
99.8
(99.4–100) 10.2
Self-careHPV 1.00 12.7(11.0–14.6)
91.7
(64.6–98.5)
88.0
(86.2–89.7)
6.4
(3.6–11.1)
99.9
(99.5–100) 15.5
2.00 9.9(8.4–11.6)
75.0
(46.8–91.1)
90.7
(89.1–92.2)
6.8
(3.6–12.4)
99.8
(99.3–100) 14.8
5.00 8.1(6.8–9.7)
58.3
(32.0–80.7)
92.3
(90.7–93.6)
6.4
(3.1–12.6)
99.6
(99.1–99.8) 15.7
10.00 6.1(5.0–7.6)
33.3
(13.8–60.9)
94.1
(92.7–95.2)
4.8
(1.9–11.7)
99.4
(98.8–99.7) 20.8
Physician-
HC2 1.00
14.6
(12.8–16.6)
91.7
(64.6–98.5)
86.1
(84.1–87.8)
5.6
(3.1–9.7)
99.9
(99.5–100) 17.9
2.00 12.7(11.1–14.6)
91.7
(64.6–98.5)
88.0
(86.1–89.6)
6.4
(3.6–11.1)
99.9
(99.5–100) 15.6
5.00 11.1(9.5–12.9)
91.7
(64.6–98.5)
89.6
(87.9–91.1)
7.3
(4.1–12.7)
99.9
(99.5–100) 13.6
10.00 10.0(8.5–11.7)
91.7
(64.6–98.5)
90.7
(89.1–92.2)
8.2
(4.6–14.0)
99.9
(99.5–100) 12.3
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sensitivity of self-careHPV testing dropped drastically from
72.1% at 1.0 RLU/CO to 32.4% at 10.00 RLU/CO. Our
results are in agreement with a cross-sectional study from
China which showed that the sensitivity of self-careHPV
testing decreased much more significantly with increasing
test  positivity  cutoffs  than  that  of  physician-careHPV
testing (10). The most practical triage point for physician-
careHPV  would  be  between  1.0  to  2.0  RLU/CO  for
CIN2+ and 1.0 to 5.0 RLU/CO for CIN3+ if setting 80%
of sensitivity as the bottom limit. However, because the
sensitivity of primary self-careHPV testing at 1.0 RLU/CO
as positivity cutoff for both CIN2+ and CIN3+ detection
was  below  80%,  it  is  not  good  to  triage  HPV-positive
women  by  increasing  self-careHPV  positive  cutoff.
Moreover,  these results  also indicate that  more specific
biomarkers with acceptable sensitivity should be developed
In  our  study,  the  screening  strategy  sensitivities  of
primary  physician-careHPV  testing  and  self-careHPV
testing, with further triage by increasing cutoff points, were
comparable among women aged 30 to 44 years and women
aged 45 to 54 years. This is in contrast to a pooled study
which showed that the optimal cutoff points and clinical
performance  of  physician-careHPV  testing  and  self-
careHPV  testing  depend  on  the  age  of  the  targeted
population to be screened (16). Perhaps the conclusions
from  our  study  are  limited  by  a  smaller  sample  size
compared  to  the  pooled  analyses,  and  further  studies
should be conducted to clarify the effect of age on HPV
testing performance.
The performance of  a  screening strategy that  triages
HPV-positive women with a second screening test whose
performance  depends  on  provider  experience  will  have
varied outcomes. VIA, an affordable, easy-to-perform test
that is suitable for LRS (17), is subjective and depends on
provider experience (18). The sensitivity of primary VIA
screening in this  study 39.7% for CIN2+ detection was
lower than that of the SPOCCS I study in China (71%)
(19), and that of VIA in controlled study settings (50%) and
in a  pooled analysis  of  studies  in  China (54.6%) (6,20).
While SPOCCS I had well-trained gynecologists providing
VIA examinations,  this  and  other  studies  utilized  local
physicians. Our data show that VIA triage of either primary
Table 4 (continued )
Age (year) Primaryscreening
Positivity
cutoff
(RLU/CO)
% (95% CI) Colposcopy
per CIN3+ (N)Referral rate Sensitivity Specificity PPV NPV
45 to 54 Physician-
careHPV 1.00
16.7
(14.5–19.2)
81.8
(52.3–94.9)
84.0
(81.5–86.2)
5.5
(2.9–10.0)
99.8
(99.1–99.9) 18.3
2.00 13.8(11.8–16.1)
81.8
(52.3–94.9)
87.0
(84.7–89.0)
6.6
(3.5–12.1)
99.8
(99.1–99.9) 15.1
5.00 12.0(10.1–14.1)
81.8
(52.3–94.9)
88.8
(86.7–90.7)
7.6
(4.1–13.9)
99.8
(99.2–99.9) 13.1
10.00 9.5(7.8–11.5)
72.7
(43.3–90.3)
91.2
(89.2–92.8)
8.5
(4.4–15.9)
99.7
(99.0–99.9) 11.8
Self-careHPV 1.00 14.8(12.7–17.1)
63.6
(35.4–84.8)
85.7
(83.4–87.8)
4.8
(2.3–9.6)
99.5
(98.8–99.8) 20.9
2.00 12.3(10.4–14.5)
63.6
(35.4–84.8)
88.3
(86.2–90.2)
5.8
(2.8–11.5)
99.5
(98.8–99.8) 17.3
5.00 8.6(7.0–10.5)
54.6
(28.0–78.7)
91.9
(90.0–93.5)
7.1
(3.3–14.6)
99.4
(98.6–99.7) 14.2
10.00 6.9(5.5–8.6)
45.5
(21.3–72.0)
93.6
(91.8–94.9)
7.4
(3.2–16.1)
99.3
(98.6–99.7) 13.6
Physician-
HC2 1.00
18.9
(16.6–21.5)
100
(74.1–100)
82.0
(79.4–84.3)
5.9
(3.3–10.2)
100
(99.5–100) 17.0
2.00 16.4(14.2–18.9)
100
(74.1–100)
84.5
(82.1–86.7)
6.8
(3.8–11.7)
100
(99.5–100) 14.7
5.00 14.9(12.8–17.3)
100
(74.1–100)
86.1
(83.8–88.1)
7.5
(4.2–12.9)
100
(99.5–100) 13.4
10.00 13.6(11.6–15.9)
90.9
(62.3–98.4)
87.3
(85.1–89.2)
7.5
(4.1–13.2)
99.9
(99.3–100) 13.4
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; HC2,
Hybrid Capture 2; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
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self-careHPV or  physician-careHPV testing  decreased
sensitivity  too  low  for  population-based  screening
programs and suggest that in areas where VIA performance
is poor, other biomarkers for cervical precancerous disease
should be explored. VIA performance has been shown to
improve with provider training (21), and so in areas where
VIA performance is currently low, further provider training
can be utilized to make the screening strategy of HPV-
positive women followed by VIA triage a feasible cervical
cancer screening option. Meanwhile, the sensitivity of VIA
is also related with the age, which decreases significantly in
postmenopausal  women  compared  to  premenopausal
performance  (22).  Our  results  consist  with  this
phenomenon and show that HPV DNA testing with VIA
triage was less sensitive among women 45 to 54 years old
than women 30 to 44 years old. Thus, HPV DNA testing
with  VIA  triage  is  not  suitable  for  older  women  or
postmenopausal women.
Another subjective test, cytology-based screening, has
been effective in decreasing cervical cancer incidence in
developed countries but has not achieved the same level of
success  in  LRS  because  laboratory  infrastructure  and
trained personnel are lacking (5,23). In other studies, the
sensitivity of one smear to detect high-grade CIN ranged
from 50% to 70% (24,25),  due to variation in provider
experience. In our study, the performance of cytology in
primary  screening  (sensitivity  of  85.3%  for  CIN2+
detection) was better than that of other studies, because the
slides were reviewed by well-trained cytopathologists from
CICAMS with international quality control as opposed to
local physicians, who are often under-trained. Therefore,
our data showing that triage of self-careHPV or physician-
careHPV positive women by cytology offers  acceptable
parameters of sensitivity and specificity, should be taken
with  caution.  Our  results  illustrate  that  high-quality
cytology would be a good triage method for HPV-positive
women.  However  not  all  programs  have  established
cytology infrastructure and well-trained cytopathologists.
Further  training in  reading cervical  cytology slides  can
produce  greater  accuracy  (26),  but  the  cost  of  the
infrastructure needed for cytology may prohibit cytology as
a secondary screening test in LRS. Again, adopting this
strategy for a screening program depends on the available
resources weighed against the needs of the program.
In  LRS  where  women  are  not  screened  for  cervical
cancer regularly,  careHPV offers an acceptable primary
screening  method.  Self-careHPV is  a  valuable  tool  for
women without easy access to cervical cancer screening.
Further studies are needed to find the suitable cutoffs for
careHPV testing that maintain high sensitivity, acceptable
specificity and increased PPV. Ideally,  HPV DNA test-
positive  women should be followed up within a  year  to
check for persistent infection or disease progression (27), in
order  to  avoid  unnecessary  treatment  of  those  with
transient or non-progressing HPV infections. However,
frequent follow-up of women is often not possible in LRS,
which points to the need to triage HPV DNA test-positive
women  for  further  referral  and  colposcopy  screening.
Regarding HPV test positive triage methods, both VIA and
cytology  are  subjective  tests,  and  as  such,  can  perform
poorly  in  areas  where  providers  are  under-trained.
Objective tests, such as HPV DNA test positivity cutoffs,
can be used reliably even in LRS. Our results also point to
the  need to  develop a  novel  object  biomarker  to  triage
HPV DNA test-positive women in LRS.
This  study had several  advantages.  All  woman in this
study with a positive screening test received colposcopy and
diagnostic biopsy, including four-quadrant punch biopsies
when no suspicious lesion was observed in colposcopy, to
minimize  disease  misclassification.  Senior  CICAMS
pathologists  read  all  histological  and  cytological  slides.
Furthermore,  the  population-based design of  the  study
determined the feasibility of conducting self-HPV testing
in rural China.
The study does have limitations. Samples from liquid-
based cytology and HC2 DNA testing were processed in
the  CICAMS  laboratory  in  Beijing,  China,  a  national
laboratory,  and therefore do not reflect  how these tests
would perform in rural areas of China, which could have
lower  performance.  Furthermore,  the  performances  of
triage models were simulated. The accuracy of screening
algorithms  presented  should  also  be  conducted  with  a
greater  number  of  high-grade  CIN  cases  to  increase
statistical power.
Conclusions
Our study demonstrates that triaging HPV test-positive
women by VIA, in areas where this test has poor sensitivity,
was  unfavorable,  unless  VIA  provider  training  can  be
implemented to increase VIA screening performance. In
areas where there is a high-quality cytology program, triage
by cytology could be a feasible option. Utilizing a suitable
HPV DNA test positivity cutoff to triage HPV test-positive
women  supplies  another  triage  option  for  LRS.  Each
country should select  a  screening strategy based on the
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resources available and their target population, as no single
screening program is a fit for all situations.
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Table S1 Clinical performance of physician- and self-collected careHPV testing in primary and triage screening strategies, stratified by age,
for CIN2+ detection among 2,337 women
Primary
screening
Triage
strategy
Age
(year)
CIN2+
(N=68)
% (95% CI) Colposcopy
per CIN2+
(N)Sensitivity Specificity PPV NPV
Youden’s
index
Physician-
careHPV ≥
1.0 RLU/CO
ASC-
US+
30 to 44 32 82.1(67.3–91.0)
96.1
(94.9–97.0)
38.6
(28.8–49.3)
99.4
(98.9–99.7) 78.2 2.6
45 to 54 23 79.3(61.6–90.2)
93.4
(91.7–94.8)
26.7
(18.5–36.9)
99.3
(98.6–99.7) 72.7 3.7
VIA
30 to 44 13 33.3(20.6–49.0)
99.0
(98.3–99.4)
50.0
(32.1–67.9)
98.0
(97.1–98.7) 32.3 2.0
45 to 54   8 27.6(14.7–45.7)
99.4
(98.6–99.7)
57.1
(32.6–78.6)
97.8
(96.7–98.6) 27.0 1.8
Self-
careHPV ≥
1.0 RLU/CO
ASC-
US+
30 to 44 29 74.4(58.9–85.4)
96.9
(95.8–97.7)
41.4
(30.6–53.1)
99.2
(98.6–99.6) 71.2 2.4
45 to 54 16 55.2(37.5–71.6)
95.7
(94.2–96.8)
28.1
(18.1–40.8)
98.6
(97.6–99.2) 50.9 3.6
VIA
30 to 44 13 33.3(20.6–49.0)
99.0
(98.3–99.4)
50.0
(32.1–67.9)
98.0
(97.1–98.7) 32.3 2.0
45 to 54   5 17.2(7.6–34.5)
99.5
(99.6–100)
50.0
(23.7–76.3)
97.5
(96.4–98.3) 16.7 2.0
Physician-
HC2 ≥1.0
RLU/CO
AS-
CUS+
30 to 44 37 94.9(83.1–98.6)
95.2
(93.9–96.2)
37.0
(28.2–46.8)
99.8
(99.4–100) 90.1 2.7
45 to 54 26 89.7(73.6–96.4)
93.2
(91.4–94.6)
28.6
(20.3–38.6)
99.7
(99.0–99.9) 82.9 3.5
VIA
30 to 44 16 41.0(27.1–56.6)
98.9
(98.1–99.3)
51.6
(34.8–68.0)
98.3
(97.4–98.8) 39.9 1.9
45 to 54 10 34.5(19.9–52.7)
99.3
(98.5–99.6)
58.8
(36.0–78.4)
98.0
(97.0–98.4) 33.8 1.7
HPV, human papillomavirus; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; RLU/CO, relative light units/cutoff; HC2,
Hybrid Capture 2; ASC-US+, atypical squamous cells of undetermined significance or worse; VIA, visual inspection with acetic acid;
95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
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Table S2 Clinical performance of physician- and self-collected careHPV testing in primary and triage screening strategies, stratified by age,
for CIN3+ detection among 2,337 women
Primary
screening
Triage
strategy
Age
(year)
CIN3+
(N=23)
% (95% CI) Colposcopy
per CIN3+
(N)Sensitivity Specificity PPV NPV
Youden’s
index
Physician-
careHPV ≥
1.0 RLU/CO
ASC-
US+
30 to 44 10 83.3(55.2–95.3)
94.5
(93.2–95.6)
12.0
(6.7–20.8)
99.8
(99.4–100) 77.9 8.3
45 to 54   9 81.8(52.3–94.9)
92.1
(90.2–93.6)
10.5
(5.6–18.7)
99.8
(99.2–99.9) 73.9 9.6
VIA
30 to 44   7 58.3(32.0–80.7)
98.6
(97.8–99.1)
26.9
(13.7–46.1)
99.6
(99.1–99.8) 56.9 3.7
45 to 54   5 45.5(28.0–78.7)
99.1
(98.3–99.5)
35.7
(16.3–61.2)
99.4
(98.7–99.7) 44.5 2.8
Self-
careHPV ≥
1.0 RLU/CO
ASC-
US+
30 to 44   9 75.0(46.8–91.1)
95.4
(94.2–96.4)
12.9
(6.9–22.7)
99.8
(99.3–99.9) 70.4 7.8
45 to 54   7 63.6(35.4–84.8)
94.9
(93.3–96.1)
12.3
(6.1–23.2)
99.6
(98.9–99.8) 58.5 8.1
VIA
30 to 44   7 58.3(32.0–80.7)
98.6
(97.8–99.1)
26.9
(13.7–46.1)
99.6
(99.1–99.8) 56.9 3.7
45 to 54   3 27.3(9.7–56.6)
99.3
(98.4–99.6)
30.0
(10.8–60.3)
99.2
(98.4–99.6) 26.6 3.3
Physician-
HC2 ≥1.0
RLU/CO
ASC-
US+
30 to 44 10 83.3(55.2–95.3)
93.3
(91.8–94.5)
10.0
(5.5–17.4)
99.8
(99.6–100) 76.6 10.0
45 to 54 11 100(74.1–100)
91.8
(89.9–93.4)
12.1
(6.9–20.4)
100
(99.4–100) 91.8 8.3
VIA
30 to 44   7 58.3(32.0–80.7)
98.2
(97.3–98.8)
22.6
(11.4–39.8)
99.6
(99.1–99.8) 56.5 4.4
45 to 54   6 54.5(28.0–78.7)
98.9
(98.0–99.4)
35.3
(17.3–58.7)
99.5
(98.0–99.4) 53.4 2.8
HPV, human papillomavirus; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; RLU/CO, relative light units/cutoff; HC2,
Hybrid Capture 2; ASC-US+, atypical squamous cells of undetermined significance or worse; VIA, visual inspection with acetic acid;
95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
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